New Stock News | Livzon Pharmaceutical submits application to Hong Kong Stock Exchange, core product AP301 has completed phase III registration clinical trials in China.

According to the Wise News Finance APP, it was learned that on October 31, the Hong Kong Stock Exchange disclosed that LiBang Pharmaceutical (Jiangsu) Co., Ltd. (referred to as LiBang Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC as joint sponsors.